Implementation studies in rare tumors is possibility

Abstract

Conference Gastrointestinal Cancers in San Francisco have presented two studies - PROMID and RADIANT-1, which evaluated the effect therapy of somatostatin analogue and everolim. Studies in the treatment of neuroendocrine tumors fail.

Keywords

• Neuroendocrine tumors
• studies
• treatment strategy